Press release
Aehealth: Advancing Global In Vitro Diagnostics with Innovation & Precision
Full-Chain Strength: Quality as the Core
Aehealth's strength lies in its end-to-end IVD ecosystem, spanning analytical reagent R&D, diagnostic instrument production, quality control (QC) validation, and post-market surveillance (PMS). Its core product lines-fluorescence immunoassay (FIA), high-performance liquid chromatography (HPLC) hemoglobin testing, hematology analyzers, and colloidal gold rapid tests-act as "health decoders" for clinical biochemical diagnosis, infectious disease screening, and chronic disease monitoring, enabling evidence-based medical decisions.
At its production base, a Class 100,000 cleanroom (ISO 14644-1 compliant) with HEPA filtration prevents cross-contamination during reagent manufacturing. The Class 10,000 laboratory focuses on antibody engineering and assay sensitivity optimization, pushing limits for limit of detection (LoD). Annual throughput hits 10 million reagent tests, with 10,000+ analyzers produced yearly-all governed by 7S management and batch traceability. Instruments undergo calibration with standard reference materials (SRMs), accelerated aging testing, and final QC per Clinical and Laboratory Standards Institute (CLSI) guidelines to ensure inter-laboratory reproducibility.
Quality is validated by certifications: ISO 13485, CE IVDR (EU 2017/746), and China's "National High-Tech Enterprise" title. Products like 5-part hematology analyzers are listed in Germany's DMOS database, with proven analytical specificity and stability. A robust QC system-featuring calibrated precision balances, -86 cryogenic chambers, and leakage current testers-ensures pre-analytical, analytical, and post-analytical performance.
Technological Innovation: Empowering Precision
Innovation defines Aehealth's offerings. Its FIA series, with 10-12 independent channels, supports 100+ tests: cardiac biomarkers (NT-proBNP, cTnI), tumor markers (AFP, CEA), thyroid panels (T3, T4, TSH), and infectious disease antigens (HBsAg, COVID-19). Tests deliver intra-assay CV less than or equal to 5% for speed and accuracy.
Hematology analyzers like the AerC-5 stand out: it uses semiconductor laser flow cytometry for 5-part WBC differential (neutrophils, lymphocytes), supports whole blood/prediluted modes, stores 50,000 results with scattergrams, and integrates with LIS/HIS via HL7. A veterinary-specific model offers species-tailored reference ranges for cats, dogs, and livestock.
The Laffinite II HPLC analyzer excels in diabetes care: primary tube piercing reduces errors, 18-position loaders include a STAT slot, and it meets NGSP standards for HbA1c testing (CV less than or equal to 1.5%), aiding glycemic control. Colloidal gold rapid tests (no equipment needed, 10-15 min results) serve POCT needs for COVID-19, fertility hormones (LH, -HCG), and inflammation markers (hs-CRP).
Global Reach: Trusted Worldwide
Aehealth's footprint spans 80+ countries, with 6,000+ installations in hospitals and clinics. It holds approvals from Germany's BfArM, Brazil's ANVISA, the UAE's SFDA, and India's CDSCO. Its service team provides installation qualification (IQ), operational qualification (OQ), performance qualification (PQ), and calibration support in English, partnering with local distributors for timely assistance.
Active in global forums-Medlab (Africa/Asia/Middle East), ADLM, and Hospitalar Brazil-it showcases cost-effective IVD solutions and builds partnerships.
Our Vision
Guided by "Efficiency, Dedication, Innovation, Sharing," Aehealth advances POCT miniaturization and multiplex assays to fulfill "Do Ahead of the Illness." It aims to deepen global health impact, bringing precise diagnostics to every corner.
Contact
* China: 11th Floor, Building 1B, BTR Tech Park, Shenzhen
* UK: 007 Room, 7 Charlotte Street, Manchester
Email: sales@aehealth.uk | Website: www.aehealthgroup.com [https://www.aehealthgroup.com/]
Media Contact
Company Name: Aehealth Limited
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aehealth-advancing-global-in-vitro-diagnostics-with-innovation-precision]
Country: China
Website: https://www.aehealthgroup.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aehealth: Advancing Global In Vitro Diagnostics with Innovation & Precision here
News-ID: 4351180 • Views: …
More Releases from ABNewswire
Operational Wisdom for High-Quality Development: Company Executives Attend Inamo …
On December 22, 2025, the 7th Inamori Management Philosophy Practice Conference was grandly held in Zhengding, Shijiazhuang. To accurately keep pace with the pulse of the times, draw on advanced operation and management concepts, and facilitate the sustainable and high-quality development of the enterprise, the company's senior management team was invited to this grand event. They gathered together with entrepreneurs and operation managers from all over the country, attending an…
Global Mobile Advertising Trends in 2026: Why Will Dual-Sided LED Rooftop Screen …
Looking ahead to 2026, the mobile advertising landscape is poised for significant transformation, driven by advancements in outdoor advertising technology. One of the most promising innovations is the dual-sided LED rooftop screen [https://www.3uview.com/taxi-top-led-screen-vst-b-product/], expected to become a cornerstone of outdoor advertising strategies. This article will explore emerging mobile advertising trends and the key role rooftop LED screens play in shaping the future advertising landscape.
Image: https://www.3uview.com/uploads/%E6%A1%88%E4%BE%8B2.jpg
The mobile advertising industry is experiencing…
The Columbus Statue at Columbus Circle in New York: The "Controversial Protagoni …
Located in the heart of Manhattan, Columbus Circle is the first stop for many tourists entering Central Park. The towering statue [https://www.eastsculpture.com/products/] of Columbus in the center of the circle is a familiar sight in New York's city skyline. It is not only a public art piece but also a complex story about "discovery", "colonization", "memory", and "reflection".
Basic information about Columbus Circle and the statue
Columbus Circle is located at the…
HOYEAH China's WPC Garden Shed Series Launches - Redefining Garden Space with Ec …
Image: https://ecdn6.globalso.com/upload/p/1781/image_other/2025-11/wpcgar-1.JPG
HOYEAH China, a specialist in eco-friendly composite materials, has proudly launched its new WPC Garden Shed series. Combining the superior performance of WPC (Wood-Plastic Composite) with versatile design, the collection offers outdoor solutions that balance aesthetics and functionality for patios and garden spaces - helping users unlock a fresh garden living experience.
Crafted from environmentally friendly WPC, HOYEAH China's WPC Garden Shed [https://www.hoyeahchina.com/wpc-gardening-products/] is made from a blend of recycled…
More Releases for Aehealth
Navigating the Future: Sexually Transmitted Diseases (STD) Testing Market Trends …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sexually Transmitted Diseases (STD) Testing Market Size Growth Forecast: What to Expect by 2025?
The market size for testing sexually transmitted diseases (std) has seen robust growth in the recent past. The market is projected to expand from $8.08 billion in 2024 to $8.78 billion in 2025, reflecting a…
Cardiac Marker Market worth $7.29 billion by 2030, growing at a CAGR of 9.71% - …
The "Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.
The Global Cardiac Marker Market to grow from USD 3.81 billion in 2023 to USD 7.29 billion by 2030, at a CAGR of 9.71%.
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/cardiac-marker?utm_source=openpr&utm_medium=referral&utm_campaign=sample
Cardiac markers are substances or molecules measured in the blood to diagnose…
Cardiac Marker Market worth $7.21 billion by 2030, growing at a CAGR of 9.46% - …
The "Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.
Request Sample Copy of this Report @ https://www.360iresearch.com/library/intelligence/cardiac-marker?utm_source=openpr&utm_medium=referral&utm_campaign=sample
Market Segmentation & Coverage:
This research report categorizes the Cardiac Marker Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Product, market is studied across Instruments and Reagents…
Thyroid Stimulating Hormone Detection Reagent Market Projected to Show Strong Gr …
Advance Market Analytics published a new research publication on "Thyroid Stimulating Hormone Detection Reagent Market Insights, to 2027" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Thyroid Stimulating Hormone Detection Reagent market was mainly driven by the increasing R&D spending across the world.
Get…
